Drug Treatment of Rheumatic Diseases in the 1990s

This publication has 86 references indexed in Scilit:

• A unifying hypothesis for the mechanism of NSAID related gastrointestinal toxicity.
  Annals of the Rheumatic Diseases, 1996
• A Six-Month Double-Blind Trial to Compare the Efficacy and Safety of Meloxicam 7.5 mg Daily and Naproxen 750 mg Daily in Patients with Rheumatoid Arthritis
  Rheumatology, 1996
• Anti-inflammatory, analgesic, antipyretic and related properties of meloxicam, a new non-steroidal anti-inflammatory agent with favourable gastrointestinal tolerance
  Inflammation Research, 1995
• Deflazacort
  Drugs, 1995
• Osteoarthritis in the Aged
  Drugs & Aging, 1995
• Tenidap: A Novel Cytokine-modulating Antirheumatic Drug for the Treatment of Rheumatoid Arthritis
  Scandinavian Journal of Rheumatology, 1994
• Treatment of rheumatoid arthritis with chimeric monoclonal antibodies to tumor necrosis factor α
  Arthritis & Rheumatism, 1993
• The American college of rheumatology preliminary core set of disease activity measures for rheumatoid arthritis clinical trials
  Arthritis & Rheumatism, 1993
• Leflunomide (HWA 486), a novel immunomodulating compound for the treatment of autoimmune disorders and reactions leading to transplantation rejection
  Inflammation Research, 1991
• Immunopharmacological profile of a novel isoxazol derivative, HWA 486, with potential antirheumatic activity — I. Disease modifying action on adjuvant arthritis of the rat
  International Journal of Immunopharmacology, 1985